We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AdvaMed: FDA Plan on Subpop Data Must Not Require ‘Enormous’ Trials
AdvaMed: FDA Plan on Subpop Data Must Not Require ‘Enormous’ Trials
An FDA action plan on subgroup analysis, currently in the works, could make device trials excessively large and expensive by imposing unnecessary requirements, AdvaMed warns.